Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656418 · ClinicalTrials.gov registry record · Phase 3
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT04656418 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 64 participants.
The verdict
NCT04656418, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.
Interventions
- DRUG Placebo
- BIOLOGICAL CSL312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656418
The ClinicalTrials.gov registry entry for NCT04656418 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04656418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04656418 about?
NCT04656418 is a clinical study titled "CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks". This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.
What is the current status of trial NCT04656418?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2021-01-27. Estimated completion is 2022-06-07.
What interventions are being tested in trial NCT04656418?
The interventions under investigation include: Placebo (DRUG), CSL312 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04656418?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.